International Journal of Clinical and Diagnostic Research
ISSN (Print): 2395-3403 ISSN (Online): 2395-3403 Website: https://www.sciepub.com/journal/ijcdr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
International Journal of Clinical and Diagnostic Research. 2017, 5(2), 45-49
DOI: 10.12691/ijcdr-5-2-2
Open AccessArticle

PRIMARY SQUAMOUS CELL CARCINOMA BREAST: A RARE CASE REPORT

Neha Kakkar1, Garima Singh2, , Deepti Sharma3, Ajay Gupta4 and Fousia Siraj5

1Department of Radiation Oncology, VMMC & Safdarjung Hospital, New Delhi -110029

2Department of Radiation Oncology, VMMC & Safdarjung Hospital, New Delhi -110030

3Department of Radiation Oncology, VMMC & Safdarjung Hospital, New Delhi -110031

4Department of Radiation Oncology, VMMC & Safdarjung Hospital, New Delhi -110032

5Department of Pathology, VMMC & Safdarjung Hospital, New Delhi -110029

Pub. Date: April 12, 2017
Full Text PDF (549 KB)

Cite this paper:
Neha Kakkar, Garima Singh, Deepti Sharma, Ajay Gupta and Fousia Siraj. PRIMARY SQUAMOUS CELL CARCINOMA BREAST: A RARE CASE REPORT. International Journal of Clinical and Diagnostic Research. 2017; 5(2):45-49. doi: 10.12691/ijcdr-5-2-2

Abstract

Primary Squamous Cell Carcinoma breast is a rare malignancy. SCC of the breast was first reported by Troell in 1908.The etiology and pathogenesis of squamous cell carcinoma of the breast is still unclear. It is thought to arise directly from the epithelium of the mammary ducts, although an alternate theory is that the tumor arises from foci of squamous metaplasia within a preexisting adenocarcinoma of the breast.These tumors are usually hormone receptor and human epidermal growth factor receptor negative. It is an aggressive tumour with poor prognosis frequently refractory to the conventional chemotherapy for breast cancer. Here we are presenting a case report of a primary squamous cell carcinoma of the breast with brief review of the literature.

Keywords:
Squamous cell carcinoma Receptor negative Anthracyclin Taxane chemotherapy

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/